BNTX:NSD-BioNTech SE (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 87.21

Change

0.00 (0.00)%

Market Cap

USD 21.93B

Volume

0.36M

Analyst Target

USD 79.79
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-04-28 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

+4.72 (+1.00%)

USD 121.32B
REGN Regeneron Pharmaceuticals Inc

-4.54 (-0.49%)

USD 103.77B
ALNY Alnylam Pharmaceuticals Inc

-3.20 (-1.12%)

USD 36.83B
ARGX argenx NV ADR

-1.17 (-0.21%)

USD 33.21B
BGNE BeiGene Ltd

-10.54 (-4.87%)

USD 24.57B
MRNA Moderna Inc

-0.50 (-0.91%)

USD 20.52B
RPRX Royalty Pharma Plc

+0.04 (+0.15%)

USD 16.47B
UTHR United Therapeutics Corporatio..

+8.60 (+2.44%)

USD 15.69B
SMMT Summit Therapeutics PLC

-3.18 (-14.57%)

USD 15.13B
PCVX Vaxcyte Inc

+0.55 (+0.52%)

USD 13.95B

ETFs Containing BNTX

MSGR 6.26 % 0.00 %

N/A

N/A
HVAX:CA 4.97 % 0.00 %

N/A

N/A
GNOG:LSE Global X Genomics & Biote.. 4.81 % 0.00 %

+0.02 (+0.42%)

USD 5.77M
GNOM Global X Genomics & Biote.. 4.80 % 0.00 %

-0.02 (0.42%)

USD 0.08B
GN0M:XETRA Global X Genomics & Biote.. 4.78 % 0.00 %

N/A

USD 7.05M
GNOM:SW Global X Genomics & Biote.. 4.78 % 0.00 %

N/A

USD 5.93M
XDNA:CA iShares Genomics Immunolo.. 4.68 % 0.00 %

+0.03 (+0.42%)

CAD 5.23M
CURG:LSE VanEck Genomics and Healt.. 4.52 % 0.00 %

+0.06 (+0.42%)

USD 5.12M
CDNA:CA CI Bio-Revolution Index E.. 3.64 % 0.00 %

N/A

CAD 6.10M
MEDTE:PA BNP Paribas Easy ECPI Glo.. 2.62 % 0.00 %

-0.07 (0.42%)

N/A
MTUSD:PA BNP Paribas Easy ECPI Glo.. 2.62 % 0.00 %

-0.06 (0.42%)

N/A
WEBA:XETRA Amundi US Tech 100 Equal .. 1.47 % 0.00 %

-0.12 (0.42%)

USD 0.62B
GERM 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -17.37% 40% F 29% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -17.37% 40% F 28% F
Trailing 12 Months  
Capital Gain -23.66% 50% F 31% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -23.66% 50% F 31% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 72.60% 89% A- 93% A
Dividend Return 72.60% 89% A- 93% A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 151.54% 16% F 10% F
Risk Adjusted Return 47.91% 92% A 79% B-
Market Capitalization 21.93B 99% N/A 96% N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.